Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

CTS Tampa Implements New Laboratory Information System

On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...

Read More >

CTS Charlotte Implements New Laboratory Information System

On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...

Read More >

FDA Guidance ZIKV Testing Strategy Webinar

On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...

Read More >

CTS Portland Implements New Laboratory Information System

On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...

Read More >

Reminder- Re-entry Webinar

Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...

Read More >